Wilding JPH - Search Results

1

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection.

Brown E, Wilding JPH, Alam U, Barber TM, Karalliedde J, Cuthbertson DJ. Brown E, et al. Among authors: wilding jph. Ann Med. 2021 Dec;53(1):2072-2089. doi: 10.1080/07853890.2020.1841281. Ann Med. 2021. PMID: 33107349 Free PMC article. Review.

2

Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.

Nair S, Wilding JP. Nair S, et al. J Clin Endocrinol Metab. 2010 Jan;95(1):34-42. doi: 10.1210/jc.2009-0473. Epub 2009 Nov 5. J Clin Endocrinol Metab. 2010. PMID: 19892839 Review.

3

A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus.

Thondam SK, Cuthbertson DJ, Aditya BS, Macfarlane IA, Wilding JP, Daousi C. Thondam SK, et al. Clin Endocrinol (Oxf). 2012 Oct;77(4):635-7. doi: 10.1111/j.1365-2265.2012.04368.x. Clin Endocrinol (Oxf). 2012. PMID: 22356092 No abstract available.

4

Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.

Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group. Wilding JP, et al. Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003. Ann Intern Med. 2012. PMID: 22431673 Free article. Clinical Trial.

5

Effects of chronic treatment with metformin on dipeptidyl peptidase-4 activity, glucagon-like peptide 1 and ghrelin in obese patients with Type 2 diabetes mellitus.

Thondam SK, Cross A, Cuthbertson DJ, Wilding JP, Daousi C. Thondam SK, et al. Diabet Med. 2012 Aug;29(8):e205-10. doi: 10.1111/j.1464-5491.2012.03675.x. Diabet Med. 2012. PMID: 22486277

6

Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic.

Steele CA, Cuthbertson DJ, MacFarlane IA, Javadpour M, Das KS, Gilkes C, Wilding JP, Daousi C. Steele CA, et al. Eur J Endocrinol. 2013 Mar 15;168(4):501-7. doi: 10.1530/EJE-12-0792. Print 2013 Apr. Eur J Endocrinol. 2013. PMID: 23293322

7

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes.

Boyle LD, Wilding JP. Boyle LD, et al. Expert Opin Emerg Drugs. 2013 Sep;18(3):375-91. doi: 10.1517/14728214.2013.831405. Expert Opin Emerg Drugs. 2013. PMID: 23968378 Review.

8

Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle.

Cuthbertson DJ, Irwin A, Sprung VS, Jones H, Pugh CJ, Daousi C, Adams VL, Bimson WE, Shojaee-Moradie F, Richardson P, Umpleby AM, Wilding JP, Kemp GJ. Cuthbertson DJ, et al. Clin Sci (Lond). 2014 Dec;127(12):655-63. doi: 10.1042/CS20130404. Clin Sci (Lond). 2014. PMID: 24738611

9

The role of the kidneys in glucose homeostasis in type 2 diabetes: clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors.

Wilding JP. Wilding JP. Metabolism. 2014 Oct;63(10):1228-37. doi: 10.1016/j.metabol.2014.06.018. Epub 2014 Jul 2. Metabolism. 2014. PMID: 25104103 Free article. Review.

10

Impact of bariatric surgery on physical functioning in obese adults.

Steele T, Cuthbertson DJ, Wilding JP. Steele T, et al. Obes Rev. 2015 Mar;16(3):248-58. doi: 10.1111/obr.12247. Epub 2015 Jan 12. Obes Rev. 2015. PMID: 25580667 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

335 results

Search Page

Filters